Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
-

Ratings ESG MSCI

Ratings Orthocell Limited: Strengths and Weaknesses

Highlights: Orthocell Limited
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses: Orthocell Limited
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.

Rating Financials

Orthocell Limited SectorAustralia

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings

Rating Valuation

Orthocell Limited SectorAustralia

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings

Rating Consensus

Orthocell Limited SectorAustralia

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

-

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

-

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Orthocell Limited SectorAustralia

Visibility

-

Analysts' coverage

-

Financial estimates divergence

-

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

-

Rating Revisions

Orthocell Limited SectorAustralia

Financial revisions

-

Revenue revisions (1 year)

-

Revenue revisions (4 months)

EPS revisions (1 year)

-

EPS revisions (4 months)

-

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
14Cr - - - - - -
17TCr
BBB
15TCr
BBB
13TCr
A
6.97TCr
BBB
4.9TCr
AAA
4.47TCr
BBB
3.67TCr
AA
3.49TCr
AAA
2.96TCr
A
Average 7.12TCr
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. OCC Stock
  4. Ratings Orthocell Limited
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!